— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.
— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.
— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.
— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.
— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.
— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.
— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.
— SNY stock was up about 4% in the pre-market trading session.
Most Popular
Target Corp posts strong results in Q4: Infographic
Target Corporation (NYSE: TGT) reported fourth-quarter 2020 financial results before the opening bell today. The department store chain reported Q4 revenue of $28.3 billion, up 21% year-over-year and higher than
Key highlights from Autodesk (ADSK) Q4 2021 earnings results
Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per
Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%
Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus
